Vismodegib
- Generic Name
- Vismodegib
- Brand Names
- Erivedge
- Drug Type
- Small Molecule
- Chemical Formula
- C19H14Cl2N2O3S
- CAS Number
- 879085-55-9
- Unique Ingredient Identifier
- 25X868M3DS
- Background
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO). It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling p...
- Indication
用于不能手术或放疗的局部晚期皮肤基底细胞癌患者和肿瘤已转移的患者。
- Associated Conditions
- Locally Advanced Basal Cell Carcinoma, Metastatic Basal cell carcinoma
- Associated Therapies
- -
A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2018-07-20
- Target Recruit Count
- 9
- Registration Number
- NCT02115828
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 673
- Registration Number
- NCT02091141
- Locations
- 🇺🇸
University Of Chicago Medical Center; Section Of Hematology/Oncology, Chicago, Illinois, United States
🇺🇸MD Anderson, Houston, Texas, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML
- Conditions
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Sarit Assouline
- Target Recruit Count
- 23
- Registration Number
- NCT02073838
- Locations
- 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada
Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
- First Posted Date
- 2014-02-20
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 9
- Registration Number
- NCT02067104
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-09-18
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 31
- Registration Number
- NCT01944943
- Locations
- 🇫🇷
CHRU de Lille _ Hôpital Huriez, Lille, France
🇫🇷CHU de Nantes _ Hôtel Dieu, Nantes, France
🇫🇷Centre Henri Becquerel, Rouen, France
A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01898598
- Locations
- 🇺🇸
Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT01880437
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
- First Posted Date
- 2013-06-17
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 660
- Registration Number
- NCT01878617
- Locations
- 🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸Texas Children's Cancer Center, Houston, Texas, United States
🇺🇸Children's Hospital and Clinics of Minnesota, Minneapolis, Minnesota, United States
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Sue Yom
- Target Recruit Count
- 24
- Registration Number
- NCT01835626
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
- First Posted Date
- 2013-03-21
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 229
- Registration Number
- NCT01815840
- Locations
- 🇺🇸
Skin and Cancer Associates and the Center for Cosmetic Enhancement, Plantation, Florida, United States
🇺🇸Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇨🇦Dermetics, Burlington, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.